Symbols / GILD $132.90 -0.29% Gilead Sciences, Inc.
GILD Chart
About
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients. Further, it provides AmBisome, for the treatment of serious invasive fungal infections; and Veklury for the treatment of COVID-19. The company has collaboration agreements with Shenzhen Pregene Biopharma Co., Ltd.; Abingworth; Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.
Fundamentals
Scroll to Statements| Market Cap | 164.96B | Enterprise Value | 181.31B | Income | 8.51B | Sales | 29.44B | Book/sh | 18.29 | Cash/sh | 7.74 |
| Dividend Yield | 2.46% | Payout | 46.61% | Employees | 17000 | IPO | — | P/E | 19.60 | Forward P/E | 13.81 |
| PEG | 0.38 | P/S | 5.60 | P/B | 7.27 | P/C | — | EV/EBITDA | 12.44 | EV/Sales | 6.16 |
| Quick Ratio | 1.23 | Current Ratio | 1.55 | Debt/Eq | 112.92 | LT Debt/Eq | — | EPS (ttm) | 6.78 | EPS next Y | 9.62 |
| EPS Growth | 23.40% | Revenue Growth | 4.70% | Earnings | 2026-04-23 | ROA | 12.52% | ROE | 40.66% | ROIC | — |
| Gross Margin | 78.84% | Oper. Margin | 37.38% | Profit Margin | 28.90% | Shs Outstand | 1.24B | Shs Float | 1.24B | Short Float | 1.74% |
| Short Ratio | 3.56 | Short Interest | — | 52W High | 157.29 | 52W Low | 93.37 | Beta | 0.40 | Avg Volume | 6.85M |
| Volume | 6.29M | Target Price | $158.36 | Recom | Buy | Prev Close | $133.29 | Price | $132.90 | Change | -0.29% |
Valuation Models
Price estimates from analyst targets and simple models.
Ratings
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-04-13 | main | Citigroup | Buy → Buy | $165 |
| 2026-04-10 | main | Morgan Stanley | Overweight → Overweight | $175 |
| 2026-03-10 | init | Jefferies | — → Buy | $180 |
| 2026-02-23 | reit | Needham | Buy → Buy | $170 |
| 2026-02-20 | init | Barclays | — → Equal-Weight | $155 |
| 2026-02-11 | main | RBC Capital | Sector Perform → Sector Perform | $118 |
| 2026-02-11 | main | Truist Securities | Buy → Buy | $152 |
| 2026-02-11 | main | Wells Fargo | Overweight → Overweight | $165 |
| 2026-02-11 | main | Cantor Fitzgerald | Overweight → Overweight | $155 |
| 2026-02-11 | main | Scotiabank | Sector Outperform → Sector Outperform | $177 |
| 2026-02-11 | main | Needham | Buy → Buy | $170 |
| 2026-01-27 | main | Truist Securities | Buy → Buy | $145 |
| 2026-01-27 | main | Citigroup | Buy → Buy | $156 |
| 2026-01-26 | main | UBS | Buy → Buy | $155 |
| 2026-01-13 | main | Morgan Stanley | Overweight → Overweight | $150 |
| 2026-01-07 | main | Citigroup | Buy → Buy | $140 |
| 2025-12-12 | main | Morgan Stanley | Overweight → Overweight | $151 |
| 2025-12-10 | main | Wells Fargo | Overweight → Overweight | $150 |
| 2025-11-13 | main | Needham | Buy → Buy | $140 |
| 2025-11-13 | init | Scotiabank | — → Sector Outperform | $140 |
- Gilead schedules May 7 earnings release, 4:30 p.m. webcast - Stock Titan Wed, 22 Apr 2026 20
- Gilead Sciences Deploys $16 Billion in 60 Days: Is GILD Stock Undervalued for 2026? - TIKR.com ue, 21 Apr 2026 14
- Assessing Gilead Sciences (GILD) Valuation After Recent Share Price Weakness And Long Term Gains - simplywall.st Wed, 22 Apr 2026 10
- 3 Reasons to Avoid GILD and 1 Stock to Buy Instead - Yahoo Finance Wed, 18 Mar 2026 07
- How Low Can Gilead Sciences Stock Really Go? - Trefis Mon, 09 Mar 2026 07
- $GILD stock is down 3% today. Here's what we see in our data. - Quiver Quantitative hu, 05 Mar 2026 08
- Gilead Sciences, Inc. (GILD) Stock Analysis: A Healthcare Giant with a 15% Upside Potential - DirectorsTalk Interviews ue, 21 Apr 2026 08
- Andrew Dickinson Sells 3,000 Shares of Gilead Sciences (NASDAQ:GILD) Stock - MarketBeat hu, 16 Apr 2026 23
- Gilead Sciences stock price forecast: limited upside as GILD trades near support after weekly decline - Traders Union Wed, 22 Apr 2026 17
- Should You Buy, Hold, or Sell GILD Stock Ahead of Q4 Earnings? - Yahoo Finance hu, 05 Feb 2026 08
- Arcellx holders get 3 more days as Gilead clears final deal approvals - Stock Titan Fri, 17 Apr 2026 12
- Gilead Sciences, Inc. $GILD Stock Holdings Lowered by Assetmark Inc. - MarketBeat Fri, 17 Apr 2026 07
- Gilead Sciences Stock To $192? - Trefis Wed, 04 Mar 2026 08
- Gilead Sciences (GILD) Stock Declines While Market Improves: Some Information for Investors - Yahoo Finance Mon, 05 Jan 2026 08
- Why Gilead Sciences (GILD) Stock Is Up Today - Yahoo Finance Fri, 19 Dec 2025 08
Insider Transactions
Financials
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
29,442.00
+2.39%
|
28,754.00
+6.04%
|
27,116.00
-0.60%
|
27,281.00
|
| Operating Revenue |
|
29,442.00
+2.39%
|
28,754.00
+6.04%
|
27,116.00
-0.60%
|
27,281.00
|
| Cost Of Revenue |
|
6,234.00
-0.27%
|
6,251.00
-3.80%
|
6,498.00
+14.87%
|
5,657.00
|
| Reconciled Cost Of Revenue |
|
6,234.00
-0.27%
|
6,251.00
-3.80%
|
6,498.00
+14.87%
|
5,657.00
|
| Gross Profit |
|
23,208.00
+3.13%
|
22,503.00
+9.14%
|
20,618.00
-4.65%
|
21,624.00
|
| Operating Expense |
|
11,507.00
-3.36%
|
11,907.00
+1.08%
|
11,780.00
+10.61%
|
10,650.00
|
| Research And Development |
|
5,799.00
-1.83%
|
5,907.00
+3.31%
|
5,718.00
+14.89%
|
4,977.00
|
| Selling General And Administration |
|
5,708.00
-4.87%
|
6,000.00
-1.02%
|
6,062.00
+6.86%
|
5,673.00
|
| Selling And Marketing Expense |
|
3,522.00
+2.00%
|
3,453.00
+5.53%
|
3,272.00
|
—
|
| General And Administrative Expense |
|
2,186.00
-14.17%
|
2,547.00
-8.71%
|
2,790.00
|
—
|
| Other Gand A |
|
2,186.00
-14.17%
|
2,547.00
-8.71%
|
2,790.00
|
—
|
| Total Expenses |
|
17,741.00
-2.30%
|
18,158.00
-0.66%
|
18,278.00
+12.09%
|
16,307.00
|
| Operating Income |
|
11,701.00
+10.43%
|
10,596.00
+19.89%
|
8,838.00
-19.46%
|
10,974.00
|
| Total Operating Income As Reported |
|
10,022.00
+503.01%
|
1,662.00
-78.15%
|
7,605.00
+3.75%
|
7,330.00
|
| EBITDA |
|
13,580.00
+206.27%
|
4,434.00
-57.76%
|
10,496.00
+18.57%
|
8,852.00
|
| Normalized EBITDA |
|
14,809.00
+8.55%
|
13,642.00
+14.68%
|
11,896.00
-9.56%
|
13,153.00
|
| Reconciled Depreciation |
|
2,760.00
-0.25%
|
2,767.00
+2.75%
|
2,693.00
+28.06%
|
2,103.00
|
| EBIT |
|
10,820.00
+549.07%
|
1,667.00
-78.64%
|
7,803.00
+15.62%
|
6,749.00
|
| Total Unusual Items |
|
-1,229.00
+86.65%
|
-9,208.00
-557.71%
|
-1,400.00
+67.45%
|
-4,301.00
|
| Total Unusual Items Excluding Goodwill |
|
-1,229.00
+86.65%
|
-9,208.00
-557.71%
|
-1,400.00
+67.45%
|
-4,301.00
|
| Special Income Charges |
|
-1,680.00
+81.20%
|
-8,934.00
-624.57%
|
-1,233.00
+66.16%
|
-3,644.00
|
| Other Special Charges |
|
1,024.00
-78.04%
|
4,663.00
+303.72%
|
1,155.00
+22.35%
|
944.00
|
| Restructuring And Mergern Acquisition |
|
66.00
-27.47%
|
91.00
+225.00%
|
28.00
|
—
|
| Write Off |
|
590.00
-85.89%
|
4,180.00
+8260.00%
|
50.00
-98.15%
|
2,700.00
|
| Net Income |
|
8,510.00
+1672.92%
|
480.00
-91.53%
|
5,665.00
+23.37%
|
4,592.00
|
| Pretax Income |
|
9,796.00
+1319.71%
|
690.00
-89.94%
|
6,859.00
+17.97%
|
5,814.00
|
| Net Non Operating Interest Income Expense |
|
-675.00
+3.02%
|
-696.00
-22.54%
|
-568.00
+31.48%
|
-829.00
|
| Interest Expense Non Operating |
|
1,024.00
+4.81%
|
977.00
+3.50%
|
944.00
+0.96%
|
935.00
|
| Net Interest Income |
|
-675.00
+3.02%
|
-696.00
-22.54%
|
-568.00
+31.48%
|
-829.00
|
| Interest Expense |
|
1,024.00
+4.81%
|
977.00
+3.50%
|
944.00
+0.96%
|
935.00
|
| Interest Income Non Operating |
|
349.00
+24.20%
|
281.00
-25.27%
|
376.00
+254.72%
|
106.00
|
| Interest Income |
|
349.00
+24.20%
|
281.00
-25.27%
|
376.00
+254.72%
|
106.00
|
| Other Income Expense |
|
-1,230.00
+86.64%
|
-9,210.00
-552.73%
|
-1,411.00
+67.41%
|
-4,330.00
|
| Other Non Operating Income Expenses |
|
-1.00
+50.00%
|
-2.00
+81.82%
|
-11.00
+62.07%
|
-29.00
|
| Gain On Sale Of Security |
|
451.00
+264.60%
|
-274.00
-64.07%
|
-167.00
+74.58%
|
-657.00
|
| Tax Provision |
|
1,286.00
+509.48%
|
211.00
-83.08%
|
1,247.00
-0.08%
|
1,248.00
|
| Tax Rate For Calcs |
|
0.00
-57.07%
|
0.00
+68.02%
|
0.00
-15.21%
|
0.00
|
| Tax Effect Of Unusual Items |
|
-161.34
+94.27%
|
-2,815.78
-1005.09%
|
-254.80
+72.40%
|
-923.23
|
| Net Income Including Noncontrolling Interests |
|
8,510.00
+1672.92%
|
480.00
-91.45%
|
5,613.00
+22.93%
|
4,566.00
|
| Net Income From Continuing Operation Net Minority Interest |
|
8,510.00
+1672.92%
|
480.00
-91.53%
|
5,665.00
+23.37%
|
4,592.00
|
| Net Income From Continuing And Discontinued Operation |
|
8,510.00
+1672.92%
|
480.00
-91.53%
|
5,665.00
+23.37%
|
4,592.00
|
| Net Income Continuous Operations |
|
8,510.00
+1676.62%
|
479.00
-91.46%
|
5,612.00
+22.91%
|
4,566.00
|
| Minority Interests |
|
0.00
|
0.00
-100.00%
|
52.00
+100.00%
|
26.00
|
| Normalized Income |
|
9,577.66
+39.37%
|
6,872.22
+0.91%
|
6,810.20
-14.55%
|
7,969.77
|
| Net Income Common Stockholders |
|
8,510.00
+1672.92%
|
480.00
-91.53%
|
5,665.00
+23.37%
|
4,592.00
|
| Diluted EPS |
|
6.78
+1684.21%
|
0.38
-91.56%
|
4.50
+23.63%
|
3.64
|
| Basic EPS |
|
6.84
+1700.00%
|
0.38
-91.63%
|
4.54
+24.04%
|
3.66
|
| Basic Average Shares |
|
1,244.00
-0.24%
|
1,247.00
-0.08%
|
1,248.00
-0.56%
|
1,255.00
|
| Diluted Average Shares |
|
1,255.00
+0.00%
|
1,255.00
-0.24%
|
1,258.00
-0.32%
|
1,262.00
|
| Diluted NI Availto Com Stockholders |
|
8,510.00
+1672.92%
|
480.00
-91.53%
|
5,665.00
+23.37%
|
4,592.00
|
| Line Item | Trend | 2023-12-31 |
|---|---|---|
| Total Assets |
|
62,125.00
|
| Current Assets |
|
16,085.00
|
| Cash Cash Equivalents And Short Term Investments |
|
7,264.00
|
| Cash And Cash Equivalents |
|
6,085.00
|
| Other Short Term Investments |
|
1,179.00
|
| Receivables |
|
4,660.00
|
| Accounts Receivable |
|
4,660.00
|
| Gross Accounts Receivable |
|
5,495.00
|
| Allowance For Doubtful Accounts Receivable |
|
-836.00
|
| Inventory |
|
1,787.00
|
| Prepaid Assets |
|
—
|
| Other Current Assets |
|
2,374.00
|
| Total Non Current Assets |
|
46,040.00
|
| Net PPE |
|
5,317.00
|
| Gross PPE |
|
7,766.00
|
| Accumulated Depreciation |
|
-2,449.00
|
| Properties |
|
0.00
|
| Land And Improvements |
|
561.00
|
| Buildings And Improvements |
|
4,328.00
|
| Machinery Furniture Equipment |
|
1,069.00
|
| Construction In Progress |
|
661.00
|
| Other Properties |
|
1,147.00
|
| Goodwill And Other Intangible Assets |
|
34,768.00
|
| Goodwill |
|
8,314.00
|
| Other Intangible Assets |
|
26,454.00
|
| Investments And Advances |
|
1,163.00
|
| Non Current Deferred Assets |
|
—
|
| Non Current Deferred Taxes Assets |
|
—
|
| Other Non Current Assets |
|
4,792.00
|
| Total Liabilities Net Minority Interest |
|
39,376.00
|
| Current Liabilities |
|
11,280.00
|
| Payables And Accrued Expenses |
|
5,560.00
|
| Payables |
|
1,758.00
|
| Accounts Payable |
|
550.00
|
| Current Accrued Expenses |
|
3,802.00
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
1,201.00
|
| Total Tax Payable |
|
1,208.00
|
| Income Tax Payable |
|
1,208.00
|
| Current Debt And Capital Lease Obligation |
|
1,798.00
|
| Current Debt |
|
1,798.00
|
| Other Current Liabilities |
|
2,334.00
|
| Total Non Current Liabilities Net Minority Interest |
|
28,096.00
|
| Long Term Debt And Capital Lease Obligation |
|
23,189.00
|
| Long Term Debt |
|
23,189.00
|
| Tradeand Other Payables Non Current |
|
2,039.00
|
| Non Current Deferred Liabilities |
|
1,588.00
|
| Non Current Deferred Taxes Liabilities |
|
1,588.00
|
| Other Non Current Liabilities |
|
1,280.00
|
| Stockholders Equity |
|
22,833.00
|
| Common Stock Equity |
|
22,833.00
|
| Capital Stock |
|
1.00
|
| Common Stock |
|
1.00
|
| Preferred Stock |
|
0.00
|
| Share Issued |
|
1,246.04
|
| Ordinary Shares Number |
|
1,246.04
|
| Treasury Shares Number |
|
0.00
|
| Additional Paid In Capital |
|
6,500.00
|
| Retained Earnings |
|
16,304.00
|
| Gains Losses Not Affecting Retained Earnings |
|
28.00
|
| Minority Interest |
|
-84.00
|
| Other Equity Adjustments |
|
28.00
|
| Total Equity Gross Minority Interest |
|
22,749.00
|
| Total Capitalization |
|
46,022.00
|
| Working Capital |
|
4,805.00
|
| Invested Capital |
|
47,820.00
|
| Total Debt |
|
24,987.00
|
| Net Debt |
|
18,902.00
|
| Net Tangible Assets |
|
-11,935.00
|
| Tangible Book Value |
|
-11,935.00
|
| Available For Sale Securities |
|
1,163.00
|
| Current Provisions |
|
387.00
|
| Investmentin Financial Assets |
|
1,163.00
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
10,019.00
-7.47%
|
10,828.00
+35.25%
|
8,006.00
-11.75%
|
9,072.00
|
| Cash Flow From Continuing Operating Activities |
|
10,019.00
-7.47%
|
10,828.00
+35.27%
|
8,005.00
-11.76%
|
9,072.00
|
| Net Income From Continuing Operations |
|
8,510.00
+1672.92%
|
480.00
-91.45%
|
5,613.00
+22.93%
|
4,566.00
|
| Depreciation Amortization Depletion |
|
2,760.00
-0.25%
|
2,767.00
+2.75%
|
2,693.00
+28.06%
|
2,103.00
|
| Depreciation |
|
370.00
-2.89%
|
381.00
+7.63%
|
354.00
+9.60%
|
323.00
|
| Amortization Cash Flow |
|
2,390.00
+0.17%
|
2,386.00
+2.01%
|
2,339.00
+31.40%
|
1,780.00
|
| Depreciation And Amortization |
|
2,760.00
-0.25%
|
2,767.00
+2.75%
|
2,693.00
+28.06%
|
2,103.00
|
| Amortization Of Intangibles |
|
2,390.00
+0.17%
|
2,386.00
+2.01%
|
2,339.00
+31.40%
|
1,780.00
|
| Other Non Cash Items |
|
1,504.00
-70.02%
|
5,016.00
+153.08%
|
1,982.00
+14.97%
|
1,724.00
|
| Stock Based Compensation |
|
894.00
+7.07%
|
835.00
+9.01%
|
766.00
+20.25%
|
637.00
|
| Asset Impairment Charge |
|
590.00
-85.89%
|
4,180.00
+8260.00%
|
50.00
-98.15%
|
2,700.00
|
| Deferred Tax |
|
160.00
+108.68%
|
-1,844.00
-91.68%
|
-962.00
+38.02%
|
-1,552.00
|
| Deferred Income Tax |
|
160.00
+108.68%
|
-1,844.00
-91.68%
|
-962.00
+38.02%
|
-1,552.00
|
| Operating Gains Losses |
|
-451.00
-264.60%
|
274.00
+64.07%
|
167.00
-74.58%
|
657.00
|
| Gain Loss On Investment Securities |
|
-451.00
-264.60%
|
274.00
+64.07%
|
167.00
-74.58%
|
657.00
|
| Change In Working Capital |
|
-3,948.00
-348.64%
|
-880.00
+61.79%
|
-2,303.00
-30.63%
|
-1,763.00
|
| Change In Receivables |
|
-367.00
-364.03%
|
139.00
-11.46%
|
157.00
+138.67%
|
-406.00
|
| Changes In Account Receivables |
|
-367.00
-364.03%
|
139.00
-11.46%
|
157.00
+138.67%
|
-406.00
|
| Change In Inventory |
|
-1,036.00
-143.19%
|
-426.00
+49.41%
|
-842.00
-171.61%
|
-310.00
|
| Change In Prepaid Assets |
|
-311.00
-20.08%
|
-259.00
-764.10%
|
39.00
+129.10%
|
-134.00
|
| Change In Payables And Accrued Expense |
|
-126.00
-131.66%
|
398.00
+258.56%
|
111.00
+120.22%
|
-549.00
|
| Change In Accrued Expense |
|
6.00
-94.44%
|
108.00
-76.42%
|
458.00
+159.10%
|
-775.00
|
| Change In Payable |
|
-132.00
-145.52%
|
290.00
+183.57%
|
-347.00
-253.54%
|
226.00
|
| Change In Account Payable |
|
-132.00
-145.52%
|
290.00
+183.57%
|
-347.00
-253.54%
|
226.00
|
| Change In Other Working Capital |
|
-2,108.00
-187.98%
|
-732.00
+58.60%
|
-1,768.00
-385.71%
|
-364.00
|
| Investing Cash Flow |
|
-4,793.00
-38.97%
|
-3,449.00
-52.27%
|
-2,265.00
+8.15%
|
-2,466.00
|
| Cash Flow From Continuing Investing Activities |
|
-4,794.00
-39.00%
|
-3,449.00
-52.21%
|
-2,266.00
+8.11%
|
-2,466.00
|
| Net PPE Purchase And Sale |
|
-563.00
-7.65%
|
-523.00
+10.60%
|
-585.00
|
—
|
| Purchase Of PPE |
|
-563.00
-7.65%
|
-523.00
+10.60%
|
-585.00
|
—
|
| Capital Expenditure |
|
-563.00
-7.65%
|
-523.00
+10.60%
|
-585.00
+19.64%
|
-728.00
|
| Capital Expenditure Reported |
|
—
|
-523.00
+10.60%
|
-585.00
+19.64%
|
-728.00
|
| Net Investment Purchase And Sale |
|
-3,163.00
-270.42%
|
1,856.00
+451.52%
|
-528.00
-980.00%
|
60.00
|
| Purchase Of Investment |
|
-4,072.00
-453.26%
|
-736.00
+68.97%
|
-2,372.00
-22.14%
|
-1,942.00
|
| Sale Of Investment |
|
909.00
-64.93%
|
2,592.00
+40.56%
|
1,844.00
-7.89%
|
2,002.00
|
| Net Business Purchase And Sale |
|
-1,070.00
+77.89%
|
-4,840.00
-320.14%
|
-1,152.00
+35.89%
|
-1,797.00
|
| Purchase Of Business |
|
-1,070.00
+77.89%
|
-4,840.00
-320.14%
|
-1,152.00
+35.89%
|
-1,797.00
|
| Net Other Investing Changes |
|
3.00
-94.83%
|
58.00
|
—
|
-1.00
|
| Financing Cash Flow |
|
-7,745.00
-125.60%
|
-3,433.00
+33.01%
|
-5,125.00
+20.78%
|
-6,469.00
|
| Cash Flow From Continuing Financing Activities |
|
-7,745.00
-125.60%
|
-3,433.00
+33.03%
|
-5,126.00
+20.76%
|
-6,469.00
|
| Net Issuance Payments Of Debt |
|
-1,788.00
-219.68%
|
1,494.00
+653.33%
|
-270.00
+82.00%
|
-1,500.00
|
| Issuance Of Debt |
|
0.00
-100.00%
|
3,464.00
+74.95%
|
1,980.00
|
0.00
|
| Repayment Of Debt |
|
-1,788.00
+9.24%
|
-1,970.00
+12.44%
|
-2,250.00
-50.00%
|
-1,500.00
|
| Long Term Debt Issuance |
|
0.00
-100.00%
|
3,464.00
+74.95%
|
1,980.00
|
0.00
|
| Long Term Debt Payments |
|
-1,788.00
+9.24%
|
-1,970.00
+12.44%
|
-2,250.00
-50.00%
|
-1,500.00
|
| Net Long Term Debt Issuance |
|
-1,788.00
-219.68%
|
1,494.00
+653.33%
|
-270.00
+82.00%
|
-1,500.00
|
| Net Common Stock Issuance |
|
-1,514.00
-107.97%
|
-728.00
+5.21%
|
-768.00
+29.35%
|
-1,087.00
|
| Common Stock Payments |
|
-1,922.00
-67.13%
|
-1,150.00
-15.00%
|
-1,000.00
+28.37%
|
-1,396.00
|
| Common Stock Dividend Paid |
|
-4,003.00
-2.17%
|
-3,918.00
-2.86%
|
-3,809.00
-2.70%
|
-3,709.00
|
| Cash Dividends Paid |
|
-4,003.00
-2.17%
|
-3,918.00
-2.86%
|
-3,809.00
-2.70%
|
-3,709.00
|
| Repurchase Of Capital Stock |
|
-1,922.00
-67.13%
|
-1,150.00
-15.00%
|
-1,000.00
+28.37%
|
-1,396.00
|
| Net Other Financing Charges |
|
-440.00
-56.58%
|
-281.00
-1.08%
|
-278.00
-60.69%
|
-173.00
|
| Changes In Cash |
|
-2,519.00
-163.84%
|
3,946.00
+540.58%
|
616.00
+349.64%
|
137.00
|
| Effect Of Exchange Rate Changes |
|
92.00
+330.00%
|
-40.00
-170.18%
|
57.00
+190.48%
|
-63.00
|
| Beginning Cash Position |
|
9,991.00
+64.19%
|
6,085.00
+12.44%
|
5,412.00
+1.39%
|
5,338.00
|
| End Cash Position |
|
7,564.00
-24.29%
|
9,991.00
+64.19%
|
6,085.00
+12.44%
|
5,412.00
|
| Free Cash Flow |
|
9,456.00
-8.24%
|
10,305.00
+38.86%
|
7,421.00
-11.06%
|
8,344.00
|
| Interest Paid Supplemental Data |
|
1,036.00
+8.94%
|
951.00
+6.73%
|
891.00
-1.76%
|
907.00
|
| Income Tax Paid Supplemental Data |
|
3,215.00
+15.69%
|
2,779.00
-30.35%
|
3,990.00
+27.23%
|
3,136.00
|
| Change In Income Tax Payable |
|
—
|
—
|
—
|
-568.00
|
| Change In Tax Payable |
|
—
|
—
|
—
|
-568.00
|
| Common Stock Issuance |
|
408.00
-3.32%
|
422.00
+81.90%
|
232.00
-24.92%
|
309.00
|
| Issuance Of Capital Stock |
|
408.00
-3.32%
|
422.00
+81.90%
|
232.00
-24.92%
|
309.00
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 42026-04-16 View
- 42026-04-16 View
- 42026-03-30 View
- 42026-03-17 View
- 42026-03-17 View
- 42026-03-12 View
- 42026-03-12 View
- 42026-03-12 View
- 42026-03-12 View
- 42026-03-12 View
- 42026-03-12 View
- 42026-03-02 View
- 42026-03-02 View
- 42026-03-02 View
- 42026-03-02 View
- 42026-03-02 View
- 10-K2026-02-24 View
- 8-K2026-02-23 View
- 42026-02-18 View
- 42026-02-18 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|